Hansen Background: Response of treatment based on pegylated inter-feron (PEG-IFN) in chronic hepatitis B (CHB) infection is still low, therefor, the strategy of response-guided therapy (RGT) has become the current focus. The efficacy of on-treatment HBsAg levels guiding therapy of PEG-IFN in CHB is still controversial. Aim: click here To evaluate the efficacy of this RGT strategy on guiding treatment of CHB infection in PEG-IFN based therapy, we conducted a comprehensive meta-analysis in which patients were given PEG-IFN with or without
nucleot(s)ide analogs (NAs), and then to judge the correlation of on-treatment HBsAg levels with response of 24 weeks off-therapy. Methods: We searched PUBMED, EMBASE, learn more the Cochrane Library (1997-2013) for clinical researches involving the HBsAg quantification and response of PEG-IFN based therapy in CHB infection. The response rate was the primary outcomes measured from the collected studies. The HBsAg clearance
of 24 weeks off-therapy was other outcomes measured. Results: Among thirteen studies (N = 1493 patients), patients with a optimal on-treatment HBsAg levels had higher chance to achieve response (RR=5.17, 95%CI: 3.75-7.11), and the pooled date of total response rate was 54% (95% CI: 44-63%). At week 12, patients without this optimal on-treatment HBsAg levels hardly achieved MycoClean Mycoplasma Removal Kit a response (the early
non-response rate: 99%, 95%CI: 98-100%). According the RGT strategy at 24 weeks, response rate could be increased to 48% and 79% in HBeAg-positive and negative patients respectively. And the corresponding pooled HBsAg clearance rate of 24 weeks off-therapy can improve to 10.9% (37/340). Conclusions: The RGT strategy using on-treatment HBsAg quantification is effective for predicting and improving the response of PEG-IFN based therapy in CHB patients, especially in HBeAg-negative patients. And this strategy might contribute to guide treatment and conduct early stopping rules. Finally, this strategy might be benefit to improve the HBsAg clearance. Disclosures: The following people have nothing to disclose: Hong Peng, Fang Wei, Junying Liu, Huaidong Hu, Peng Hu, Hong Ren Background: Little is known about stopping rules of nucelos(t) ide analog (NA) treatment for chronic hepatitis B (CHB). Methods: A total of 164 consecutive CHB patients who met cessation criteria of NA treatment by APASL guideline were enrolled in this prospective study. Fifty-one patients were excluded by exclusion criteria, 113 patients (45 HBeAg-positive and 68 HBeAg-negative CHB), who stopped NA treatment, remained for statistical analysis.